|
1
|
Malvezzi M, Bertuccio P, Levi F, La
Vecchia C and Negri E: European cancer mortality predictions for
the year 2014. Ann Oncol. 25:1650–1656. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ducreux M, Cuhna AS, Caramella C,
Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van
Laethem JL, Conroy T, et al: ESMO Guidelines Committee: Cancer of
the pancreas: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 26(Suppl 5): v56–v68. 2015.
View Article : Google Scholar
|
|
3
|
Andersson R, Aho U, Nilsson BI, Peters GJ,
Pastor-Anglada M, Rasch W and Sandvold ML: Gemcitabine
chemoresistance in pancreatic cancer: Molecular mechanisms and
potential solutions. Scand J Gastroenterol. 44:782–786. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Williams TM and Lisanti MP: The Caveolin
genes: From cell biology to medicine. Ann Med. 36:584–595. 2004.
View Article : Google Scholar
|
|
5
|
Chen T, Liu L, Xu HX, Wang WQ, Wu CT, Yao
WT and Yu XJ: Significance of caveolin-1 regulators in pancreatic
cancer. Asian Pac J Cancer Prev. 14:4501–4507. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boscher C and Nabi IR: Caveolin-1: Role in
cell signaling. Adv Exp Med Biol. 729:29–50. 2012. View Article : Google Scholar
|
|
7
|
Del Pozo MA and Schwartz MA: Rac, membrane
heterogeneity, caveolin and regulation of growth by integrins.
Trends Cell Biol. 17:246–250. 2007. View Article : Google Scholar
|
|
8
|
Wary KK, Mariotti A, Zurzolo C and
Giancotti FG: A requirement for caveolin-1 and associated kinase
Fyn in integrin signaling and anchorage-dependent cell growth.
Cell. 94:625–634. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goetz JG, Lajoie P, Wiseman SM and Nabi
IR: Caveolin-1 in tumor progression: The good, the bad and the
ugly. Cancer Metastasis Rev. 27:715–735. 2008. View Article : Google Scholar
|
|
10
|
Suzuoki M, Miyamoto M, Kato K, Hiraoka K,
Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh
T, et al: Impact of caveolin-1 expression on prognosis of
pancreatic ductal adenocarcinoma. Br J Cancer. 87:1140–1144. 2002.
View Article : Google Scholar
|
|
11
|
Tanase CP, Dima S, Mihai M, Raducan E,
Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM,
Leabu M, et al: Caveolin-1 overexpression correlates with tumour
progression markers in pancreatic ductal adenocarcinoma. J Mol
Histol. 40:23–29. 2009. View Article : Google Scholar
|
|
12
|
Nam KH, Lee BL, Park JH, Kim J, Han N, Lee
HE, Kim MA, Lee HS and Kim WH: Caveolin 1 expression correlates
with poor prognosis and focal adhesion kinase expression in gastric
cancer. Pathobiology. 80:87–94. 2013. View Article : Google Scholar
|
|
13
|
Han F, Zhang J, Shao J and Yi X:
Caveolin-1 promotes an invasive phenotype and predicts poor
prognosis in large cell lung carcinoma. Pathol Res Pract.
210:514–520. 2014. View Article : Google Scholar
|
|
14
|
Ando T, Ishiguro H, Kimura M, Mitsui A,
Mori Y, Sugito N, Tomoda K, Mori R, Harada K, Katada T, et al: The
overexpression of caveolin-1 and caveolin-2 correlates with a poor
prognosis and tumor progression in esophageal squamous cell
carcinoma. Oncol Rep. 18:601–609. 2007.
|
|
15
|
Huang C, Qiu Z, Wang L, Peng Z, Jia Z,
Logsdon CD, Le X, Wei D, Huang S and Xie K: A novel FoxM1-caveolin
signaling pathway promotes pancreatic cancer invasion and
metastasis. Cancer Res. 72:655–665. 2012. View Article : Google Scholar
|
|
16
|
Lin M, DiVito MM, Merajver SD, Boyanapalli
M and van Golen KL: Regulation of pancreatic cancer cell migration
and invasion by RhoC GTPase and caveolin-1. Mol Cancer. 4:212005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye Y, Miao SH, Lu RZ and Zhou JW:
Prognostic value of caveolin-1 expression in gastric cancer: A
meta-analysis. Asian Pac J Cancer Prev. 15:8367–8370. 2014.
View Article : Google Scholar
|
|
18
|
Witkiewicz AK, Dasgupta A, Sotgia F,
Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR and Lisanti MP:
An absence of stromal caveolin-1 expression predicts early tumor
recurrence and poor clinical outcome in human breast cancers. Am J
Pathol. 174:2023–2034. 2009. View Article : Google Scholar
|
|
19
|
Ma X, Liu L, Nie W, Li Y, Zhang B, Zhang J
and Zhou R: Prognostic role of caveolin in breast cancer: A
meta-analysis. Breast. 22:462–469. 2013. View Article : Google Scholar
|
|
20
|
Zhao Z, Han FH, Yang SB, Hua LX, Wu JH and
Zhan WH: Loss of stromal caveolin-1 expression in colorectal cancer
predicts poor survival. World J Gastroenterol. 21:1140–1147. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shan T, Lu H, Ji H, Li Y, Guo J, Chen X
and Wu T: Loss of stromal caveolin-1 expression: A novel tumor
microenvironment biomarker that can predict poor clinical outcomes
for pancreatic cancer. PLoS One. 9:e972392014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jia Y, Wang N, Wang J, Tian H, Ma W, Wang
K, Tan B, Zhang G, Yang S, Bai B, et al: Down-regulation of stromal
caveolin-1 expression in esophageal squamous cell carcinoma: A
potent predictor of lymph node metastases, early tumor recurrence,
and poor prognosis. Ann Surg Oncol. 21:329–336. 2014. View Article : Google Scholar
|
|
23
|
Zhao X, He Y, Gao J, Fan L, Li Z, Yang G
and Chen H: Caveolin-1 expression level in cancer associated
fibroblasts predicts outcome in gastric cancer. PLoS One.
8:e591022013. View Article : Google Scholar
|
|
24
|
Nakatani K, Wada T, Nakamura M, Uzawa K,
Tanzawa H and Fujita S: Expression of caveolin-1 and its
correlation with cisplatin sensitivity in oral squamous cell
carcinoma. J Cancer Res Clin Oncol. 131:445–452. 2005. View Article : Google Scholar
|
|
25
|
Tirado OM, MacCarthy CM, Fatima N, Villar
J, Mateo-Lozano S and Notario V: Caveolin-1 promotes resistance to
chemotherapy-induced apoptosis in Ewing’s sarcoma cells by
modulating PKCalpha phosphorylation. Int J Cancer. 126:426–436.
2010. View Article : Google Scholar
|
|
26
|
Wang Z, Wang N, Liu P, Peng F, Tang H,
Chen Q, Xu R, Dai Y, Lin Y, Xie X, et al: Caveolin-1, a
stress-related oncotarget, in drug resistance. Oncotarget.
6:37135–37150. 2015.PubMed/NCBI
|
|
27
|
Hehlgans S and Cordes N: Caveolin-1: An
essential modulator of cancer cell radio-and chemoresistance. Am J
Cancer Res. 1:521–530. 2011.
|
|
28
|
Hehlgans S, Eke I, Storch K, Haase M,
Baretton GB and Cordes N: Caveolin-1 mediated radioresistance of 3D
grown pancreatic cancer cells. Radiother Oncol. 92:362–370. 2009.
View Article : Google Scholar
|
|
29
|
Salem AF, Bonuccelli G, Bevilacqua G,
Arafat H, Pestell RG, Sotgia F and Lisanti MP: Caveolin-1 promotes
pancreatic cancer cell differentiation and restores membranous
E-cadherin via suppression of the epithelial-mesenchymal
transition. Cell Cycle. 10:3692–3700. 2011. View Article : Google Scholar
|
|
30
|
Witkiewicz AK, Nguyen KH, Dasgupta A,
Kennedy EP, Yeo CJ, Lisanti MP and Brody JR: Co-expression of fatty
acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma:
Implications for tumor progression and clinical outcome. Cell
Cycle. 7:3021–3025. 2008. View Article : Google Scholar
|
|
31
|
Dimas K, Hatziantoniou S, Tseleni S, Khan
H, Georgopoulos A, Alevizopoulos K, Wyche JH, Pantazis P and
Demetzos C: Sclareol induces apoptosis in human HCT116 colon cancer
cells in vitro and suppression of HCT116 tumor growth in
immunodeficient mice. Apoptosis. 12:685–694. 2007. View Article : Google Scholar
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Iyer VR, Eisen MB, Ross DT, Schuler G,
Moore T, Lee JC, Trent JM, Staudt LM, Hudson J Jr, Boguski MS, et
al: The transcriptional program in the response of human
fibroblasts to serum. Science. 283:83–87. 1999. View Article : Google Scholar
|
|
34
|
Tsimplouli C, Demetzos C,
Hadzopoulou-Cladaras M, Pantazis P and Dimas K: In vitro activity
of dietary flavonol congeners against human cancer cell lines. Eur
J Nutr. 51:181–190. 2012. View Article : Google Scholar
|
|
35
|
Dimas K, Demetzos C, Vaos B, Marselos M
and Kokkinopoulos D: Cytotoxic and antiproliferative effects of
heptaacetyltiliroside on human leukemic cell lines. Leuk Res.
23:1021–1033. 1999. View Article : Google Scholar
|
|
36
|
Chatterjee M, Ben-Josef E, Thomas DG,
Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA,
Chen CS, Ludwig T, et al: Caveolin-1 is associated with tumor
progression and confers a multi-modality resistance phenotype in
pancreatic cancer. Sci Rep. 5:108672015. View Article : Google Scholar :
|
|
37
|
Alshenawy HA and Ali MA: Differential
caveolin-1 expression in colon carcinoma and its relation to
E-cadherin-β-catenin complex. Ann Diagn Pathol. 17:476–482. 2013.
View Article : Google Scholar
|
|
38
|
Erkan M, Kurtoglu M and Kleeff J: The role
of hypoxia in pancreatic cancer: A potential therapeutic target.
Expert Rev Gastroenterol Hepatol. 10:301–316. 2016. View Article : Google Scholar
|
|
39
|
Verbeke C: Morphological heterogeneity in
ductal adenocarcinoma of the pancreas - Does it matter.
Pancreatology. 16:295–301. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deer EL, González-Hernández J, Coursen JD,
Shea JE, Ngatia J, Scaife CL, Firpo MA and Mulvihill SJ: Phenotype
and genotype of pancreatic cancer cell lines. Pancreas. 39:425–435.
2010. View Article : Google Scholar
|
|
41
|
Han F and Zhu HG: Caveolin-1 regulating
the invasion and expression of matrix metalloproteinase (MMPs) in
pancreatic carcinoma cells. J Surg Res. 159:443–450. 2010.
View Article : Google Scholar
|
|
42
|
Cordes N, Frick S, Brunner TB, Pilarsky C,
Grützmann R, Sipos B, Klöppel G, McKenna WG and Bernhard EJ: Human
pancreatic tumor cells are sensitized to ionizing radiation by
knockdown of caveolin-1. Oncogene. 26:6851–6862. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Di Vizio D, Morello M, Sotgia F, Pestell
RG, Freeman MR and Lisanti MP: An absence of stromal caveolin-1 is
associated with advanced prostate cancer, metastatic disease and
epithelial Akt activation. Cell Cycle. 8:2420–2424. 2009.
View Article : Google Scholar
|
|
44
|
Martinez-Outschoorn UE, Pavlides S,
Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, Migneco
G, Witkiewicz AK, Martinez-Cantarin MP, Flomenberg N, et al: Tumor
cells induce the cancer associated fibroblast phenotype via
caveolin-1 degradation: Implications for breast cancer and DCIS
therapy with autophagy inhibitors. Cell Cycle. 9:2423–2433. 2010.
View Article : Google Scholar
|
|
45
|
Bonuccelli G, Whitaker-Menezes D,
Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK,
Vander Heiden MG, Migneco G, Chiavarina B, et al: The reverse
Warburg effect: Glycolysis inhibitors prevent the tumor promoting
effects of caveolin-1 deficient cancer associated fibroblasts. Cell
Cycle. 9:1960–1971. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pavlides S, Tsirigos A, Vera I, Flomenberg
N, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG,
et al: Loss of stromal caveolin-1 leads to oxidative stress, mimics
hypoxia and drives inflammation in the tumor microenvironment,
conferring the ‘reverse Warburg effect’: A transcriptional
informatics analysis with validation. Cell Cycle. 9:2201–2219.
2010. View Article : Google Scholar
|
|
47
|
Capozza F, Trimmer C, Castello-Cros R,
Katiyar S, Whitaker- Menezes D, Follenzi A, Crosariol M, Llaverias
G, Sotgia F, Pestell RG, et al: Genetic ablation of Cav1
differentially affects melanoma tumor growth and metastasis in
mice: Role of Cav1 in Shh heterotypic signaling and
transendothelial migration. Cancer Res. 72:2262–2274. 2012.
View Article : Google Scholar
|
|
48
|
Olive KP, Jacobetz MA, Davidson CJ,
Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA,
Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic
cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar
|
|
49
|
Özdemir BC, Pentcheva-Hoang T, Carstens
JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C,
Novitskiy SV, et al: Depletion of carcinoma-associated fibroblasts
and fibrosis induces immunosuppression and accelerates pancreas
cancer with reduced survival. Cancer Cell. 25:719–734. 2014.
View Article : Google Scholar
|
|
50
|
Rhim AD, Oberstein PE, Thomas DH, Mirek
ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP,
Tattersall IW, et al: Stromal elements act to restrain, rather than
support, pancreatic ductal adenocarcinoma. Cancer Cell. 25:735–747.
2014. View Article : Google Scholar
|
|
51
|
Hessmann E, Patzak MS, Klein L, Chen N,
Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, et
al: Fibroblast drug scavenging increases intratumoural gemcitabine
accumulation in murine pancreas cancer. Gut. 67:497–507. 2018.
View Article : Google Scholar :
|
|
52
|
Bocci G, Fioravanti A, Orlandi P, Di
Desidero T, Natale G, Fanelli G, Viacava P, Naccarato AG, Francia G
and Danesi R: Metronomic ceramide analogs inhibit angiogenesis in
pancreatic cancer through up-regulation of caveolin-1 and
thrombos-pondin-1 and down-regulation of cyclin D1. Neoplasia.
14:833–845. 2012. View Article : Google Scholar
|
|
53
|
Ma Y, Lin Z, Fallon JK, Zhao Q, Liu D,
Wang Y and Liu F: New mouse xenograft model modulated by
tumor-associated fibroblasts for human multi-drug resistance in
cancer. Oncol Rep. 34:2699–2705. 2015. View Article : Google Scholar
|
